A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment "I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.

A pancreatic cancer expert on why Revolution Medicines' study could 'open up a new era' of treatment | #cancer #PancreaticCancer

#AACR26

#AACR26 kicks off today and we’re proud to highlight over 50 studies including #myeloma, #pancreaticcancer, #breastcancer, #AI and genetic risk factors presented by @danafarber.bsky.social researchers. bit.ly/4cAoXMU

Pancreatic Cancer Screening: Hope for Earlier Diagnosis Uterine fibroid embolization is a minimally invasive treatment for fibroids. Discover how the UFE procedure works and how it compares to other treatments.

Earlier diagnosis could change everything in #pancreaticcancer. City of Hope has highlighted how targeted screening for high-risk people may help find the disease at a more treatable stage, when more options are still possible. #EarlyDetection#CancerAwareness #TCSC
www.cityofhope.org/hope-matters...

OHSU research reveals how pancreatic cancer blocks immunotherapy Study also identifies potential path to making immunotherapy effective against the deadly, treatment-resistant cancer.

Pancreatic cancer has been one of the toughest cancers for immunotherapy. New OHSU research helps explain why, and points toward ways to make immunotherapy more effective against this devastating disease. #PancreaticCancer #Immunotherapy #CancerResearch #TCSC
news.ohsu.edu/2026/04/10/o...

New Project Launch: Post Imaging Pancreatic Cancer Root Cause Analysis (PIPC) - healthdatainsight.org.uk

We’ve launched the Post Imaging Pancreatic Cancer (PIPC) Root Cause Analysis Project. We're managing this @nihr.bsky.social funded work with NHS partners & patient reps from @pancreaticcanuk.bsky.social to improve early #PancreaticCancer diagnosis.

🔗 Read more tinyurl.com/3ps3dn4b

Client Challenge

🎙️Prof. Ellen Heitzer from the Medical Uni Graz was recently featured in a podcast!
• Challenges of early #pancreaticcancer detection
• Liquid Biopsy
• Her research on ctDNA and MRD
• The role of PANCAID

🎧 Listen here (German only): www.springermedizin.at/meduni-graz/...

#liquidbiopsy

Congratulations to the Revolution Medicines team on the important results from the RASolute302 Phase 3 clinical study of daraxonrasib in advanced #PancreaticCancer.

As progress accelerates in targeting KRAS-driven tumors, the next step is understanding the effects of these therapies in patients.

OHSU research reveals how pancreatic cancer blocks immunotherapy Study also identifies potential path to making immunotherapy effective against the deadly, treatment-resistant cancer.

Why haven’t many immunotherapies worked in #PancreaticCancer and what's a possible solution?

New #OHSUResearch suggests treatments may need to both turn on the immune system and overcome the tumor’s own ability to shut it down.

Learn more:

New drug created at Northwestern helps pancreatic cancer patients live longer, oncologist says ABC7 talked to a widow who says the drug helped her have more time with her husband.

A new pancreatic cancer drug developed at Northwestern is offering real hope, with patients living longer in early reporting from the trial. Pancreatic cancer needs breakthroughs like this. #PancreaticCancer #CancerResearch #Oncology #TCSC
abc7chicago.com/post/new-pan...

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 stud | ...

Revolution's much height RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial | #PancreaticCancer #cancer

For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option Former Sen. Ben Sasse gives a glimpse of what it's like to be a participant in an tough but promising new drug for pancreatic cancer.

For Ben Sasse, Revolution Medicines' pancreatic cancer trial felt like his best, only option | #PancreaticCancer #cancer

Pancreatic cancer pill shown to nearly double overall survival time, drug company says - Replaye The company reports the drug showed “clinically meaningful improvements” in overall survival.

Pancreatic cancer pill shown to nearly double overall survival time, drug company says
replaye.com/pancreatic-c...

#News #Cancer #PancreaticCancer

Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.

"Revolution's drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday."

#Pancreaticcancer #cancer #science

#CancerResearch Spotlight: Senior author Mandeep Sawhney, MD, BIDMC Division of Gastroenterology, and team found patients prefer EUS for #pancreaticcancer screening, and MRCP for pancreatic cyst surveillance.

These findings support a more patient-centered, individualized screening approach.

RASolute 302 Update on #PancreaticCancer
News from Industry: Source Revolution Medicines

ir.revmed.com/news-release...

Daraxonrasib significantly improved survival in the Phase 3 RASolute 302 trial for previously treated metastatic pancreatic cancer.

A new drug doubles one-year survival in pancreatic cancer.
🙂 Another encouraging piece of news from Groupe UIG!
Read: medicalxpress.com/news/2026-04...
#Oncology #ClinicalTrials #PancreaticCancer #Biotech #Innovation #PrecisionMedicine #Healthcare

Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation - Communications Biology Upregulated HAS2 promotes pancreatic cancer immune evasion by stabilizing PD-L1 through AKT-dependent repression of the E3 ligase MARCH4. Targeting the HAS2–MARCH4–PD-L1 axis restores T-cell infiltrat...

Targeting HAS2 to enhance anti-tumor immunity in #PancreaticCancer via PD-L1 regulation 🧪 idp.nature.com/authorize?re...

Integrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Microenvironment Accurate prediction of early recurrence in pancreatic ductal adenocarcinoma is vital for optimizing treatment. A novel, integrated radiomics-pathology machine learning model successfully forecasts re...

Integrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Microenvironment advanced.onlinelibrary.wiley.com/doi/10.1002/... #PancreaticCancer 🧪

Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP - Cell Death & Disease Cell Death & Disease - Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP

Exosomal miR-92a-3p promotes #PancreaticCancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP idp.nature.com/authorize?re... 🧪

Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic #PancreaticCancer 🧪 www.biorxiv.org/content/10.6...

Ketogenic supplementation enhances KRASG12D inhibitor efficacy in pancreatic ductal adenocarcinoma

Ketogenic supplementation enhances KRASG12D inhibitor efficacy in pancreatic ductal adenocarcinoma #PancreaticCancer 🧪 www.sciencedirect.com/science/arti...

Revolution Medicines Rises on Daraxonrasib Data Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12, 2026).

Revolution Medicines Rises on Daraxonrasib Data: Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12,… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #PancreaticCancer #CancerResearch #Biotech

CA19-9 promotes liver metastasis of #PancreaticCancer through E-selectin mediated extravasation 🧪 www.biorxiv.org/content/10.6...

Revolution rockets on strong pancreatic cancer data Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib

#RevolutionMedicines thinks it could transform the treatment of #pancreaticcancer – one of the hardest forms to treat – based on phase 3 data with its pan-RAS(on) inhibitor #daraxonrasib.

pharmaphorum.com/news/revolut...

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously treated metastatic pancreatic cancer.

A new pancreatic cancer pill has nearly doubled survival in trials, offering real hope in one of the toughest cancers to treat. This is the kind of progress patients have been waiting for. #PancreaticCancer #CancerResearch #Oncology #TCSC
pancan.org/news/first-r...

Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill Revolution Medicines' daraxonrasib pill shows promising results in metastatic pancreatic cancer tria...

Revolution Medicines' daraxonrasib pill shows promising results in metastatic pancreatic cancer trial. Patients lived nearly twice as long as those on chemo. #PancreaticCancer #News

#trends today for 'pancreatic cancer' 'mental health' & 'suspected militants'

Click/Tap below:

www.newsmason.com?query=%22pan...

www.newsmason.com?query=%22men...

www.newsmason.com?query=%22sus...

#pancreaticcancer #mentalhealth #suspectedmilitants

Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill In a trial, metastatic pancreatic cancer patients on the medicine lived twice as long as those on chemotherapy.

Revolution Medicines touts 'unprecedented' data for pancreatic cancer pill | #PancreaticCancer #cancer

April 26 daraxonrasib showed major promise in Phase 3 RASolute 302 trial nearly doubling median overall survival in previously treated metastatic #pancreaticcancer Pill targets KRAS mutations Cancer cell growth. FDA approval? Approved Novocure's Optune Pax® 3 new trials PRISM1

Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial - Replaye Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.

Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
replaye.com/revolution-m...

#News #RevolutionMedicines #PancreaticCancer #Cancer #Health